International journal of laboratory hematology · 2025
Comparative Analysis of 12 Flow Cytometry-Based Markers in B-Lymphoblastic Leukemia/Lymphoma and Their Utility in Detecting Minimal/Measurable Residual Disease.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Srinivasan Tharageswari, Mallik Nabhajit, Bose Parveen, Kumar Arun, Lal Bhavishan, Jawallia Kajol, Sharma Praveen, Sreedharanunni Sreejesh, Sachdeva Man Updesh Singh, Das Reena, Khadwal Alka, Malhotra Pankaj, Tehran Amita
Аннотация
INTRODUCTION: Minimal/measurable residual disease (MRD) is a key prognostic factor in B-lymphoblastic leukemia/lymphoma (B-ALL/LBL), commonly assessed via multiparametric flow cytometry (MFC). This study evaluated 12 leukemia-associated immunophenotype (LAIP) markers-CD81, CD86, CD123, CD58, CD9, CD73, CD13/CD33, CD44, CD97, CD66c, CD49f, and CD304-to determine their suitability for MRD detection.
METHODS: Marker expression was analyzed in 103 B-ALL cases at diagnosis, and 54 post-therapy follow-up samples, including 16 MRD-positive cases. Additionally, 25 non-B-ALL bone marrow samples were examined for marker expression in hematogones. Clinical and genetic correlation was also performed.
RESULTS: Median age of patients was 9 years (range: 0.3-89), with male: female ratio of 1:1. We found that CD97, CD73, CD86, and CD58 are excellent markers for MRD analysis in B-ALL, as they are expressed in more than 85% of cases at baseline, and their expression is preserved in more than 75% of cases post-therapy. Two other extremely promising markers are CD81 and CD49f, both of which are expressed as LAIP in more than 50% of B-ALL cases, with retention of expression in more than 85% of cases post-therapy, and importantly, expression as LAIP in some post-therapy samples despite their absence at baseline. Hyperdiploidy was significantly associated with expression of CD86, CD97, CD123, CD66c, and CD9; BCR::ABL1 fusion was associated with CD49f, CD81, and CD66c.
CONCLUSION: CD97, CD73, CD86, and CD58 are the best amongst newer markers in B-ALL MRD assessment. Our findings support integrating these into MRD panels to enhance post-therapy MRD detection, thus improving prognostication and guiding treatment decisions.
METHODS: Marker expression was analyzed in 103 B-ALL cases at diagnosis, and 54 post-therapy follow-up samples, including 16 MRD-positive cases. Additionally, 25 non-B-ALL bone marrow samples were examined for marker expression in hematogones. Clinical and genetic correlation was also performed.
RESULTS: Median age of patients was 9 years (range: 0.3-89), with male: female ratio of 1:1. We found that CD97, CD73, CD86, and CD58 are excellent markers for MRD analysis in B-ALL, as they are expressed in more than 85% of cases at baseline, and their expression is preserved in more than 75% of cases post-therapy. Two other extremely promising markers are CD81 and CD49f, both of which are expressed as LAIP in more than 50% of B-ALL cases, with retention of expression in more than 85% of cases post-therapy, and importantly, expression as LAIP in some post-therapy samples despite their absence at baseline. Hyperdiploidy was significantly associated with expression of CD86, CD97, CD123, CD66c, and CD9; BCR::ABL1 fusion was associated with CD49f, CD81, and CD66c.
CONCLUSION: CD97, CD73, CD86, and CD58 are the best amongst newer markers in B-ALL MRD assessment. Our findings support integrating these into MRD panels to enhance post-therapy MRD detection, thus improving prognostication and guiding treatment decisions.